The New Rules of Retina Drug Development - Takeaways - MDSpire

The New Rules of Retina Drug Development

In a panel at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.

  • By

  • Jim Gallagher, senior managing editor

  • July 15, 2026

  • 5 min

Share

  • 1

    The Retina Innovation Summit panel discussed how evolving FDA guidance is reshaping retina drug development from clinical trials to approval.

  • 2

    Panelists emphasized the increasing importance of regulatory strategy in the development of new ophthalmic therapies.

  • 3

    The FDA's stance on sham controls in intravitreal injection studies has shifted, recognizing potential bias from patient awareness.

  • 4

    Experts advised prioritizing high-quality data collection over larger datasets to answer clinically meaningful regulatory questions.

  • 5

    Panelists agreed that early engagement with the FDA and careful evidence package construction are crucial for successful drug development.

Original Source(s)

The New Rules of Retina Drug Development

  • by Jim Gallagher, senior managing editor

  • July 15, 2026

Related Content

PCG with biallelic CYP1B1 and CPAMD8 variants: a longitudinal case report

Can Stem Cell Therapy Slow GA?

Phase 1b data for ASP7317, presented at ASRS, showed a favorable safety profile, encouraging visual acuity findings, and stabilization of geographic atrophy in patients with advanced disease.

Malpositioned orbital implants: indications for implant removal and secondary reconstructive techniques